The next wave of stroma-targeting therapy in pancreatic cancer

Huocong Huang, Rolf A Brekken

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The stroma of pancreatic ductal adenocarcinoma (PDA) forms a major barrier to therapy and immune surveillance. Elahi-Gedwillo and colleagues demonstrate that halofuginone has potent antifibrotic activity in PDA by directly inhibiting the activation of pancreatic stellate cells, thereby reducing the deposition of extracellular matrix components, including collagen and hyaluronic acid. As a result, halofuginone improves drug delivery and the infiltration of favorable immune cells such as immune-stimulatory myeloid cells and cytotoxic T cells. Despite recent controversies regarding targeting stroma in PDA, this study highlights that modifying the stroma of PDA remains an attractive strategy to improve the efficacy of therapy.

Original languageEnglish (US)
Pages (from-to)328-330
Number of pages3
JournalCancer Research
Volume79
Issue number2
DOIs
StatePublished - Jan 15 2019

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Pancreatic Stellate Cells
Myeloid Cells
Hyaluronic Acid
Therapeutics
Extracellular Matrix
Collagen
T-Lymphocytes
Pharmaceutical Preparations
halofuginone

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The next wave of stroma-targeting therapy in pancreatic cancer. / Huang, Huocong; Brekken, Rolf A.

In: Cancer Research, Vol. 79, No. 2, 15.01.2019, p. 328-330.

Research output: Contribution to journalArticle

@article{04f379bce9af414c9c21f774f27bae62,
title = "The next wave of stroma-targeting therapy in pancreatic cancer",
abstract = "The stroma of pancreatic ductal adenocarcinoma (PDA) forms a major barrier to therapy and immune surveillance. Elahi-Gedwillo and colleagues demonstrate that halofuginone has potent antifibrotic activity in PDA by directly inhibiting the activation of pancreatic stellate cells, thereby reducing the deposition of extracellular matrix components, including collagen and hyaluronic acid. As a result, halofuginone improves drug delivery and the infiltration of favorable immune cells such as immune-stimulatory myeloid cells and cytotoxic T cells. Despite recent controversies regarding targeting stroma in PDA, this study highlights that modifying the stroma of PDA remains an attractive strategy to improve the efficacy of therapy.",
author = "Huocong Huang and Brekken, {Rolf A}",
year = "2019",
month = "1",
day = "15",
doi = "10.1158/0008-5472.CAN-18-3751",
language = "English (US)",
volume = "79",
pages = "328--330",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - The next wave of stroma-targeting therapy in pancreatic cancer

AU - Huang, Huocong

AU - Brekken, Rolf A

PY - 2019/1/15

Y1 - 2019/1/15

N2 - The stroma of pancreatic ductal adenocarcinoma (PDA) forms a major barrier to therapy and immune surveillance. Elahi-Gedwillo and colleagues demonstrate that halofuginone has potent antifibrotic activity in PDA by directly inhibiting the activation of pancreatic stellate cells, thereby reducing the deposition of extracellular matrix components, including collagen and hyaluronic acid. As a result, halofuginone improves drug delivery and the infiltration of favorable immune cells such as immune-stimulatory myeloid cells and cytotoxic T cells. Despite recent controversies regarding targeting stroma in PDA, this study highlights that modifying the stroma of PDA remains an attractive strategy to improve the efficacy of therapy.

AB - The stroma of pancreatic ductal adenocarcinoma (PDA) forms a major barrier to therapy and immune surveillance. Elahi-Gedwillo and colleagues demonstrate that halofuginone has potent antifibrotic activity in PDA by directly inhibiting the activation of pancreatic stellate cells, thereby reducing the deposition of extracellular matrix components, including collagen and hyaluronic acid. As a result, halofuginone improves drug delivery and the infiltration of favorable immune cells such as immune-stimulatory myeloid cells and cytotoxic T cells. Despite recent controversies regarding targeting stroma in PDA, this study highlights that modifying the stroma of PDA remains an attractive strategy to improve the efficacy of therapy.

UR - http://www.scopus.com/inward/record.url?scp=85059960607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059960607&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-3751

DO - 10.1158/0008-5472.CAN-18-3751

M3 - Article

C2 - 30647067

AN - SCOPUS:85059960607

VL - 79

SP - 328

EP - 330

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 2

ER -